Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India".
Press Release Mar 17 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a licensing agreement with Lupin for co-marketing an innovative Semaglutide Injection in India. Under this agreement, Zydus will market the product under specific brand names while Lupin will have semi-exclusive rights to co-market it under their own brands. The partnership aims to enhance patient access to advanced therapies for diabetes and weight management.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 16 2026
- Press Release Mar 14 2026
- Press Release Mar 13 2026
- Press Release Mar 12 2026
- Press Release Feb 28 2026
Later from Zydus Lifesciences
- Press Release Mar 18 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 19 2026
- Zydus Lifesciences Limited Press Release Mar 21 2026
- Press Release Apr 08 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences